(Q87492688)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656536%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

review article

1 reference

title

Myelodysplastic syndromes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656536%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656536%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

3

Pierre Fenaux

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656536%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

1

Lionel Adès

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656536%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

language of work or name

English

0 references

publication date

21 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656536%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656536%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

volume

383

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656536%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

issue

9936

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656536%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

page(s)

2239-2252

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656536%20AND%20SRC:MED&resulttype=core&format=json

Clinical effect of point mutations in myelodysplastic syndromes

11 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Myelodysplastic Syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Revised international prognostic scoring system for myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Risk of cancer after low doses of ionising radiation: retrospective cohort study in 15 countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Occupational and environmental risk factors of the myelodysplastic syndromes in the North of France.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Exposure to myelotoxic agents and myelodysplasia: case-control study and correlation with clinicobiological findings.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Myelodysplastic syndromes: the complexity of stem-cell diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Clonal architecture of secondary acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Persistent malignant stem cells in del(5q) myelodysplasia in remission

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

L3MBTL1 polycomb protein, a candidate tumor suppressor in del(20q12) myeloid disorders, is essential for genome stability

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

The role of mutations in epigenetic regulators in myeloid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Point Mutations in Myelodysplastic Syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Frequent pathway mutations of splicing machinery in myelodysplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Splicing regulator SC35 is essential for genomic stability and cell proliferation during mammalian organogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Establishment of a xenograft model of human myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Infections in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Association between myelodysplastic syndromes and inflammatory bowel diseases. Report of seven new cases and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

A prognostic score for patients with lower risk myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and failure to identify a very-low-risk group using standard mortality ratio techniques.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinosi

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation fo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Impact of iron overload in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Antithymocyte globulin for patients with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Myelodysplastic syndromes: iron overload consequences and current chelating therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961901-7

7 January 2021

10.1016/S0140-6736(13)61901-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656536%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

1 reference